Feasibility Studies of Personalized Closed Loop

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Device: Cloud-based Digital Twin and Meal Prediction algorithms

Registration Number: NCT04203823

Lead Sponsor: Medtronic Diabetes

Brief Summary: This is a single arm study comprised of a series of feasibility studies.

Detailed Description: Feasibility Study Part 2 (i.e. Feasibility 2): Feasibility 2 is the focus of the current version of the study protocol.

This study will include 2 separate Cohorts of individuals, based on the algorithms being studied:

Cohort A: The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm adaptation

Cohort C: The main purpose of this cohort is to test a meal prediction algorithm

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 126

Inclusion Criteria

General Inclusion Criteria

Subject is age 2-80 years at time of Visit 1. Note: See staged enrollment reference for adult and pediatric subjects in the Study Design section
Subject has a clinical diagnosis of type 1 diabetes.
1. Subjects 7 years of age and older: Diagnosed at least 1 year prior to Visit 1
2. Subjects 2-6 years of age: Diagnosed at least 3 months prior to Visit 1
Study-specific inclusion criteria
Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units.
If subject has a history of hypothyroidism, must have at least 1 documented normal thyroid-stimulating hormone (TSH) on historical labs within 12 months of Visit 1. A subject without a history of hyperthyroidism is not expected to have a TSH test
Subjects and their parent(s)/guardian(s) must have Internet access , a computer system that meets the requirements for uploading the study pump and Smartphone that meets study requirements.
Subject must have a companion or caregiver available at night for the duration of the study period who resides (or will live) in in the same building (or home). This requirement may be verified by subject report at screening visit.
If subject has celiac disease, it has been adequately treated as determined by the investigator.
Subjects and their parent(s)/guardian(s) are willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
- Humalog™* (insulin lispro injection)
- NovoLog™* (insulin aspart)

Exclusion Criteria

Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the last 1 year prior to Visit 1
1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
2. Coma
3. Seizures
Subject is unable to tolerate tape adhesive in the area of sensor placement.
Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
Women of child-bearing potential who have a positive pregnancy test at Visit 1 or plan to become pregnant during the course of the study
Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
Subject has a cardiovascular condition which the Study Investigator determines should exclude the subject, e.g. ventricular rhythm disturbance, hypertrophic cardiomyopathy, recent myocardial infarction in the last year prior to Visit 1.
Subject is being treated for hyperthyroidism at time of Visit 1.
Subject has a diagnosis of adrenal insufficiency.
Subject has had Diabetic Ketoacidosis (DKA) within 1 year prior to Visit 1.
Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of visit 1, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.
Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit 1. Please note participation in observational study is acceptable.
Subject has been hospitalized or has visited the ER in the 6 months prior to Visit 1 resulting in a primary diagnosis of uncontrolled diabetes.
Subject is currently abusing illicit drugs.
Subject is currently abusing alcohol.
Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Visit 1.
Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.
Subject has elective surgery planned that requires general anesthesia during the course of the study.
Subject diagnosed with current eating disorder such as anorexia or bulimia.
Subject has been diagnosed with chronic kidney disease that results in chronic anemia.
Subject is on dialysis.
Subject has serum creatinine of >2 mg/dL, as confirmed through historical labs within 1 year prior to Visit 1.
Subject is a member the research staff involved with the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Algorithm Testing	Cloud-based Digital Twin and Meal Prediction algorithms	The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm The study population will be enrolled as 2 separate cohorts to test each algorithms individually

Primary Outcome Measures

Name	Time	Method
Number of Severe Hypoglycemic Event - Cohort C	approximately 3.5 months	Number of severe hypoglycemic events occurred in the study in Cohort C
Number of Diabetic Ketoacidosis (DKA) Event - Cohort C	approximately 3.5 months	Number of Diabetic Ketoacidosis (DKA) event occurred in the study in Cohort C
Percentage of Time in Euglycemia - Cohort C	approximately 3.5 months	The overall mean percentage of time in Euglycemia (70-180 mg/dL) in Cohort C
Number of Severe Hypoglycemic Event - Cohort A	approximately 3.5 months	Number of severe hypoglycemic events occurred in the study in Cohort A
Number of Diabetic Ketoacidosis (DKA) Event - Cohort A	approximately 3.5 months	Number of Diabetic Ketoacidosis (DKA) event occurred in the study in Cohort A
Percentage of Time in Euglycemia - Cohort A	approximately 3.5 months	The overall mean percentage of time in Euglycemia (70-180 mg/dL) in Cohort A

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (12): Diablo Clinical Research
🇺🇸
Walnut Creek, California, United States
Barbara Davis Center / Pediatric
🇺🇸
Aurora, Colorado, United States
University of South Florida Diabetes Center
🇺🇸
Tampa, Florida, United States
Atlanta Diabetes Associates
🇺🇸
Atlanta, Georgia, United States
Rocky Mountain Diabetes
🇺🇸
Idaho Falls, Idaho, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Loma Linda University Medical Center
🇺🇸
Loma Linda, California, United States
Barbara Davis Center - Adults
🇺🇸
Aurora, Colorado, United States
Endocrine Research Solutions, Inc.
🇺🇸
Roswell, Georgia, United States
Park Nicollet International Diabetes Center
🇺🇸
Saint Louis Park, Minnesota, United States
AM Diabetes and Endocrinology Center
🇺🇸
Bartlett, Tennessee, United States
Rainier Clinical Research
🇺🇸
Renton, Washington, United States